

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Japara Healthcare Limited
ABN 54 168 631 052

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Price
Date of last notice	7 October 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	11 December 2020
No. of securities held prior to change	131,894 fully paid ordinary shares allocated under the Company's Equity Incentive Plan ("Plan"), held indirectly by Pacific Custodians Pty Limited as trustee of the Japara Employee Share Trust (as Beneficiary).
Class	Performance rights
Number acquired	1,440,000 granted
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	<p>1,440,000 performance rights granted under the Plan, held directly.</p> <p>131,894 fully paid ordinary shares allocated under the Plan, held indirectly by Pacific Custodians Pty Limited as trustee of the Japara Employee Share Trust (as Beneficiary).</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>Grant of performance rights under the Plan for FY2021 long-term incentive purposes, as approved by shareholders at the Company's Annual General Meeting on 30 October 2020 ("AGM").</p> <p>These performance rights are subject to:</p> <ul style="list-style-type: none"> - a 48 month performance period from 1 July 2020 to 30 June 2024; and - a gateway hurdle and vesting conditions as set out in the Explanatory Notes accompanying the Notice of AGM.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Dated: 15 December 2020

+ See chapter 19 for defined terms.